Stock Price Quote

SUPRIYA PHARMACEUTICALS LTD.

NSE : NABSE : 524784ISIN CODE : INE647C01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE10.300 (0 %)
PREV CLOSE ( ) 10.30
OPEN PRICE ( ) 10.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )10.30 10.30
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1985
Management Info
- Chairman - Managing Director
Registered Office

Address F-530, Riico Industrial Estate, Alwar,
Bhiwadi,
Rajasthan-301019

Phone 01493- 220053 220754

Email --

Website NA

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE

NEWS

No News Found

Financials

in Millions
QTR Jun 08 ANNUAL 07
Net Profit-0.17-0.72
Gross Profit -0.17 -0.72
Operating Profit 0.21.1
Net Sales 00

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

NON-INSTITUTION 71.32%
PROMOTERS 26.94%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Supriya Pharmaceuticals Ltd.

Supriya Pharmaceuticals Ltd. was incorporated in the year 1985. Its today's share price is 10.3. Its current market capitalisation stands at Rs 6.04 Cr. In the latest quarter, company has reported Gross Sales of Rs. 32.06 Cr and Total Income of Rs.48.4 Cr. The company's management includes .

It is listed on the BSE with a BSE Code of 524784 , NSE with an NSE Symbol of and ISIN of INE647C01016. It's Registered office is at F-530, Riico Industrial Estate, AlwarBhiwadi-301019, Rajasthan. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.